Differences in Salivary Flow Level, Xerostomia, and Flavor Alteration in Mexican HIV Patients Who Did or Did Not Receive Antiretroviral Therapy
Sandra López‐Verdín(Universidad de la República de Uruguay), Nelly Molina‐Frechero(Universidad Autónoma Metropolitana), Jaime Andrade‐Villanueva(Hospital Civil de Guadalajara), Ana Lourdes Zamora-Pérez(Universidad de Guadalajara), José Justino Cervantes-Cabrera(Universidad de Guadalajara), Ronell Bologna‐Molina(Universidad de la República de Uruguay)
Cited by 21
Related Papers
Comparison of the value of PCNA and Ki-67 as markers of cell proliferation in ameloblastic tumors
|Medicina oral, patología oral y cirugía bucal|2012|253
Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial
|The Lancet Respiratory Medicine|2021|225
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
|The Lancet Infectious Diseases|2011|172
Extranodal NK/T cell lymphoma, nasal type: An updated overview
|Critical Reviews in Oncology/Hematology|2021|111
Oral Manifestations Associated with HIV/AIDS Patients
|Medicina|2022|97